Cinclus Pharma (CINPHA) Q3 2024 earnings summary

Executive summary

• Linaprazan glarate, a next-generation PCAB for severe erosive GERD, is advancing toward Phase III with preparations on track and first patient recruitment targeted for 2025.

• IPO in June 2024 secured significant financing, enabling Phase III studies, organizational strengthening, and further R&D.

• Linaprazan glarate demonstrated superior acid control and healing rates in clinical trials, with a clear FDA regulatory pathway and blockbuster potential in the US and EU.

• Strong IP portfolio with patents extending beyond 2040 and regulatory exclusivity in EU and U.S.; pediatric study plan approved by EMA.

• Manufacturing for Phase III completed; clinical CRO appointed; management team expanded.

Financial highlights

• Cash position at period end was SEK 644.3 million, up from SEK 87.9 million in Q3 2023, mainly due to the IPO.

• Net loss for Q3 2024 was SEK 36.5 million, improved from SEK 62.0 million in Q3 2023.

• R&D spending accounted for 81% of total operating expenses in Q3 2024.

• Net sales for Q3 2024 were SEK 6.0 million; no commercial product revenues yet.

• Equity at period end was SEK 606.3 million, with an equity ratio of 92%.

Outlook and guidance

• First patient in for Phase III eGERD trial expected in 2025, with healing data readout anticipated in 2026.

• Additional financing may be needed for a second Phase III study or H. pylori program, with further funding planned after key clinical milestones.

• Regulatory milestones include ongoing pediatric studies and market launch preparations, with potential first approvals in 2027.

• Licensing deals in emerging markets may occur before full Phase III completion, but approvals likely to align with U.S. and EU timelines.

• No significant sales expected in China until after reimbursement approval, which may take up to a year post-approval.